PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac™ vaccine and their relation to the antibody response to hepatitis B surface antigen
2009

Study on Newborns' Response to Hepatitis B Vaccine

Sample size: 28 publication 10 minutes Evidence: moderate

Author Information

Author(s): Ulla B Hellström, Kazimierz Madalinski, Staffan P E Sylvan

Primary Institution: Department of Communicable Disease Control and Prevention, Uppsala County Council, Sweden

Hypothesis

Does recognition of preS1 epitopes in newborns correlate with antibody response to hepatitis B surface antigen after vaccination?

Conclusion

Newborns who recognized multiple preS1 epitopes showed a stronger antibody response to the hepatitis B vaccine.

Supporting Evidence

  • 50% of newborns had detectable levels of anti-preS1 (21–32) antibodies.
  • 54% of newborns were anti-preS1 (32–47) reactive.
  • 43% of newborns were anti-preS1 (94–117) reactive.
  • Higher anti-HBs levels were observed in newborns with detectable anti-preS1 (32–47) reactivity.

Takeaway

This study found that babies who recognized more parts of a hepatitis B vaccine had better immune responses.

Methodology

28 healthy newborns were vaccinated with either 2.5 ug or 5.0 ug of the Sci-B-Vac vaccine and their antibody responses were measured at 6 and 9 months.

Potential Biases

Potential bias due to the small sample size and exclusion of certain demographics.

Limitations

The study did not explore long-term immunity or responses in different populations.

Participant Demographics

Healthy newborns, mothers negative for hepatitis B markers, and newborns with normal Apgar scores.

Statistical Information

P-Value

p<0.025

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1743-422X-6-7

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication